# Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

> **NCT03808480** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 22 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** CA and Nivolumab

## Key facts

- **NCT ID:** NCT03808480
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-23
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03808480, "Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03808480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*